Title of article :
World Hepatitis Day in Burkina Faso, 2016: Awareness, Screening,
Identification of HBV Markers, HBV/HCV Coinfection, and Vaccination
Author/Authors :
Diarra Birama نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Ouattara Abdoul Karim نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Wendkuuni Djigma Florencia نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Rebeca Compaore Tegwinde نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Obiri-Yeboah Dorcas نويسنده Department of Microbiology and Immunology, School of
Medical Sciences, University of Cape Coast, Ghana , Traore Lassina نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Theophile Soubeiga Serge نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Bado Prosper نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Yara Justine نويسنده SOS Hepatitis Burkina Faso , Pietra Virginio نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso , Ouedraogo Paul نويسنده Saint Camille Hospital of Ouagadougou (HOSCO), BP 444
Ouagadougou 01, Burkina Faso , Bougouma Alain نويسنده Gastroenterology Service, CHU Yalgado OUEDRAOGO,
Ouagadougou, Burkina Faso , Sanogo Rokia نويسنده Faculty of Pharmacy, University of Sciences of Techniques
and Technologies of Bamako (USTTB), Mali , Simpore Jacques نويسنده Biomolecular Research Center PietroAnnigoni (CERBA), BP
364 Ouagadougou 01, Burkina Faso
Abstract :
Background Hepatitis B virus (HBV) can cause chronic hepatitis,
cirrhosis, and hepatocellular carcinoma. Coinfection with hepatitis C
virus (HCV)/HBV leads to a higher risk of liver damage. Development of
HBV awareness campaigns could reduce the prevalence of this disease and
limit the consequences. Objectives The aim of this study was to
sensitize, detect, and identify HBV markers and propose vaccination for
people not infected with HBV. Methods With the support of “SOS Hepatitis
Burkina” association, an HBV screening program, available for all
volunteers, was implemented in several localities of Ouagadougou and the
surroundings. A rapid HBsAg detection test was performed on 2207
subjects, who voluntarily answered a series of questions. A rapid
detection test of HCV antibodies was performed in HBsAg-positive cases.
HBV markers were also determined in HBsAg-positive cases. Results In a
sample of 2207 individuals, aged 1 - 85 years (mean age, 31.4 ± 15.7
years), the prevalence of HBsAg was 9.8% (217/2207) after screening.
Before screening, 6.8% (150/2207) of the participants claimed that they
were vaccinated against HBV. Also, multivariate analysis revealed that
HBV infection was significantly associated with age (21 - 30 years) and
vaccination status (P = 0.03; OR, 1.67; 95% CI, 1.04 to 2.69 and P =
0.003; OR, 5.69; 95% CI, 1.80 to 18.00, respectively). Among 217
HBsAg-positive cases, the prevalence of HBV markers was reported as
follows: AbHBs (0.9%), HBeAg (6.0%), AbHBe (87.6%), and AbHBc (100.0%).
Based on the findings, HCV was detected in 0.9% (2/217) of
HBsAg-positive subjects. In this study, 628 out of 1990 HBsAg-negative
subjects were vaccinated for three doses, resulting in a vaccination
rate of 31.6%. Conclusions The present study reported an HBsAg
prevalence of 9.8% in the study population. This intervention could
contribute to major vaccination coverage against HBV after screening.
Therefore, raising awareness and development of screening campaigns on
HBV can increase the vaccination coverage of the population. The
findings also showed that absence of vaccination against HBV constitutes
a high-risk factor for HBV infection.
